Shanghai Medicilon (SHSE:688202) Beneish M-Score: -3.27 (As of Jun. 28, 2026)


SHSE:688202 Shanghai Medicilon Inc SHSE:688202
73 GF Score
Price ¥70.57
GF Value ¥46.13
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Shanghai Medicilon Beneish M-Score?

Shanghai Medicilon SHSE:688202 -1.29% 73 Beneish M-Score is -3.27 as of Jun. 28, 2026. GuruFocus rates SHSE:688202 with a GF Score™ of 73/100 and a GF Value™ of ¥46.13 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 831 Biotechnology companies, Shanghai Medicilon ranks better than 81.11% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.27 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Shanghai Medicilon's Beneish M-Score or its related term are showing as below:

SHSE:688202' s Beneish M-Score Range Over the Past 10 Years
Min: -3.73   Med: -1.75   Max: 14.1
Current: -3.27

During the past 12 years, the highest Beneish M-Score of Shanghai Medicilon was 14.10. The lowest was -3.73. And the median was -1.75.


Shanghai Medicilon Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Shanghai Medicilon's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Medicilon Beneish M-Score Chart

Shanghai Medicilon Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.85 -0.84 -2.04 -1.47 -3.47

Shanghai Medicilon Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.93 -3.73 -3.65 -3.47 -3.27

SHSE:688202 vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, Shanghai Medicilon's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Medicilon Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Medicilon's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Shanghai Medicilon's Beneish M-Score falls into.


SHSE:688202
73GF Score
Shanghai Medicilon Inc SHSE:688202
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai Medicilon Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Shanghai Medicilon for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.6932+0.528 * 0.5203+0.404 * 1.0562+0.892 * 1.206+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9571+4.679 * -0.085703-0.327 * 1.1907
=-3.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ¥534 Mil.
Revenue was 364.644 + 320.098 + 302.558 + 273.316 = ¥1,261 Mil.
Gross Profit was 95.008 + 30.383 + 56.715 + 55.934 = ¥238 Mil.
Total Current Assets was ¥1,352 Mil.
Total Assets was ¥2,766 Mil.
Property, Plant and Equipment(Net PPE) was ¥793 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥81 Mil.
Total Current Liabilities was ¥700 Mil.
Long-Term Debt & Capital Lease Obligation was ¥54 Mil.
Net Income was 15.615 + -138.143 + -16.787 + 1.648 = ¥-138 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ¥0 Mil.
Cash Flow from Operations was -4.836 + 62.697 + -32.189 + 73.729 = ¥99 Mil.
Total Receivables was ¥638 Mil.
Revenue was 267.091 + 236.02 + 280.304 + 261.915 = ¥1,045 Mil.
Gross Profit was 58.852 + 7.195 + 15.274 + 21.374 = ¥103 Mil.
Total Current Assets was ¥1,444 Mil.
Total Assets was ¥2,838 Mil.
Property, Plant and Equipment(Net PPE) was ¥790 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥70 Mil.
Total Current Liabilities was ¥524 Mil.
Long-Term Debt & Capital Lease Obligation was ¥126 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(533.594 / 1260.616) / (638.255 / 1045.33)
=0.42328 / 0.610578
=0.6932

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(102.695 / 1045.33) / (238.04 / 1260.616)
=0.098242 / 0.188828
=0.5203

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1351.508 + 792.848) / 2766.173) / (1 - (1444.214 + 790) / 2838.256)
=0.224793 / 0.212822
=1.0562

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1260.616 / 1045.33
=1.206

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 790)) / (0 / (0 + 792.848))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(81.024 / 1260.616) / (70.195 / 1045.33)
=0.064273 / 0.067151
=0.9571

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((54.148 + 699.964) / 2766.173) / ((126.316 + 523.539) / 2838.256)
=0.272619 / 0.228963
=1.1907

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-137.667 - 0 - 99.401) / 2766.173
=-0.085703

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Shanghai Medicilon has a M-score of -3.27 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -3.27 mean?
Shanghai Medicilon (SHSE:688202) has a Beneish M-Score of -3.27 as of Jun. 28, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Shanghai Medicilon and its competitors. According to the industry distribution chart, Shanghai Medicilon ranks #157 out of 831 companies in the Biotechnology industry, placing it in the top 18.9%.
Is Shanghai Medicilon's Beneish M-Score too high?
Shanghai Medicilon's current Beneish M-Score is -3.27. Based on the distribution chart, Shanghai Medicilon ranks #157 out of 831 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Shanghai Medicilon has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Medicilon's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Medicilon ranks #157 out of 831 companies for Beneish M-Score. This places Shanghai Medicilon in the top 19% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Shanghai Medicilon and its competitors. Shanghai Medicilon's current Beneish M-Score is -3.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Medicilon stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Medicilon (SHSE:688202) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥46.13, compared to a current price of ¥70.57 — trading 53% above its estimated fair value. The current Beneish M-Score is -3.27. Shanghai Medicilon's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Shanghai Medicilon (SHSE:688202), the current Beneish M-Score is -3.27 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Medicilon (SHSE:688202) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Medicilon stock appears to be overvalued. The current stock price of ¥70.57 is trading 53% above its estimated GF Value™ of ¥46.13. GuruFocus considers Shanghai Medicilon to be Significantly Overvalued.

Key valuation signals for SHSE:688202:

  • Beneish M-Score: -3.27
  • GF Value™: ¥46.13 vs. price of ¥70.57 (53% above fair value)
  • GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the SHSE:688202 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shanghai Medicilon Business Description

Address Lane 67, Libing Road, Building 5, Pilot Free Trade Zone, Shanghai, CHN, 201299
Shanghai Medicilon Inc is a comprehensive biomedical research and developemnt service company. It provides a full range of one-stop new drug development services for pharmaceutical companies and research institutions around the world in line with domestic and international reporting standards.
73GF Score

Get the complete analysis for SHSE:688202

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥70.57
Price
¥46.13
GF Value